- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04797364
Pharmacogenetic Supported Prescribing in Kids (PGx-SParK)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Children with moderate to severe mental health conditions (e.g. depression, anxiety, OCD) or neurodevelopmental disorders (e.g., autism spectrum disorders, ADHD) are frequently prescribed medications as either the sole form of treatment or in combination with psychotherapy. However, up to 50% of these children will not respond or experience burdensome adverse drug reactions to these medications. Current use of mental health-related medications (e.g., antidepressants, antipsychotics) in children can be best described as a trial-and-error process that can impact the well-being of those taking the medications and their families at a considerable economic cost. However, this trial-and-error process could, in part, be avoided through the application of pharmacogenetic testing, a specific type of genetic testing that has the potential to improve drug efficacy and reduce the morbidity, mortality and cost associated with adverse drug reactions. The aim of this project is to implement and evaluate an evidence-based pharmacogenetic testing service to improve drug treatment outcomes in children receiving mental health care.
Our objectives are to:
- Implement Canada's first pharmacogenetics testing service to improve drug treatment outcomes in children receiving mental health care.
- Collect performance, outcome, and economic indicators related to the pharmacogenetics testing service.
- Establish a research platform for the discovery of new genetic and non-genetic markers of drug treatment outcomes relevant to mental health care in children.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laina McAusland, MSc
- Phone Number: 403-210-6353
- Email: psychpgxlab@ucalgary.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- Recruiting
- University of Calgary
-
Contact:
- Laina McAusland, MSc
- Phone Number: 403-210-6353
- Email: psychpgxlab@ucalgary.ca
-
Principal Investigator:
- Chad Bousman
-
Sub-Investigator:
- Paul Arnold
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medical records available
- The initiation, change, dose adjustment, or augmentation of psychiatric medication(s) is indicated
- Treating psychiatrist, family physician, or pediatrician licensed in Alberta, British Columbia, Saskatchewan, or Manitoba requests pharmacogenetic testing
Exclusion Criteria:
- Medically unstable or lacking capacity to provided informed consent
- Unwillingness of child to provide saliva sample for genetic analysis
- History of liver or bone marrow (hematopoietic cell) transplant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmacogenetic Testing
Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)
|
Participants will donate a 2ml (teaspoon) sample of saliva.
DNA extracted from the saliva sample will be used for genotyping.
Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making.
The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse drug reactions
Time Frame: 6-months
|
Relative change in adverse drug reaction frequency
|
6-months
|
Symptom severity
Time Frame: 6-months
|
Relative change in symptom severity
|
6-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healthcare utilization
Time Frame: 6-months
|
Relative change in healthcare utilization
|
6-months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- REB20-0900
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Health Impairment
-
Boston CollegeUniversity of Georgia; Caritas Freetown; German Society for International CooperationCompletedMental Health Disorder | Mental Health Impairment | Psychosocial Impairment | Emotional DysfunctionSierra Leone
-
Stony Brook UniversityUnknownMental Health ImpairmentUnited States
-
University of BergenHaukeland University Hospital; Wisconsin Department of Health and Family Services and other collaboratorsCompleted
-
University of RoehamptonMIND Tower HamletsTerminatedMental Health ImpairmentUnited Kingdom
-
Stony Brook UniversityCompletedMental Health ImpairmentUnited States
-
McMaster UniversityHamilton Health Sciences Corporation; Ontario Mental Health Foundation; St. Joseph...CompletedMental Health ImpairmentCanada
-
University of WarwickKing's College London; KU Leuven; University Hospital, Montpellier; Erasmus Medical... and other collaboratorsUnknownMental Health Disorder | Mental Health ImpairmentIreland, United Kingdom, Netherlands, Germany, Belgium, Croatia, France, Italy
-
Haukeland University HospitalUniversity of BergenEnrolling by invitationChild, Only | Mental Health Impairment | Health Care Utilization | Multi-morbidityNorway
-
Boston CollegeUniversity of Georgia; Innovations for Poverty Action; Caritas Freetown; German...CompletedMental Health Disorder | Mental Health Impairment | Psychosocial ProblemSierra Leone
-
Mental Health Services in the Capital Region, DenmarkThe Peer partnership associationCompletedMental Health Disorder | Mental Health Impairment | Peer Group | Problems PsychosocialDenmark
Clinical Trials on Pharmacogenetic Testing
-
Avera McKennan Hospital & University Health CenterCompletedDepressionUnited States
-
Maastricht University Medical CenterKing's College London; State University of New York - Upstate Medical University and other collaboratorsRecruitingPsychotic Disorders | Mood Disorders | Anxiety DisordersUnited States, Germany, Netherlands, Spain, Serbia, Romania, United Kingdom
-
Duke UniversityNational Institute of General Medical Sciences (NIGMS)Completed
-
University of ArizonaUnknownDepression | Obsessive-Compulsive Disorder | Generalized Anxiety Disorder
-
Avera McKennan Hospital & University Health CenterCompletedEvaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes (PGx-TIME)Major Depressive Disorder 1United States
-
Anna VlasovaRussian Medical Academy of Continuous Professional Education; Morozov Children...CompletedDrug TherapyRussian Federation
-
Medstar Health Research InstituteKailos Genetics, Inc.Active, not recruitingChronic PainUnited States
-
Avera McKennan Hospital & University Health CenterCompletedMajor Depressive DisorderUnited States
-
Cairo UniversityAin Shams University; Misr International UniversityUnknown
-
Genelex CorporationHarding UniversityCompletedDrug Interaction Potentiation | Adverse Drug Events | Adverse Drug Reactions | Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant | Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant | Drug Metabolism, Poor, CYP2D6-RELATED | Drug Metabolism, Poor, CYP2C19-RELATED | Cytochrome P450 Enzyme... and other conditionsUnited States